MIRVASO® Available at FFF

For Patients With Persistent Facial Erythema of Rosacea

August 8, 2023

You may be aware that some of your patients are having trouble filling their prescriptions for oxymetazoline HCL cream, 1% at the pharmacy.

FFF Enterprises is happy to inform you that MIRVASO® (brimonidine) topical gel, 0.33%* is available to treat patients with persistent facial erythema of rosacea.

According to Galderma, in clinical trials, MIRVASO was shown to provide:

  • Rapid facial erythema reduction for up to 12 hours1
  • Sustained relief from persistent erythema of rosacea2,3
  • Demonstrated safety and tolerability2,3

Galderma helps make MIRVASO accessible and affordable for eligible patients:

  • MIRVASO is still available at your local and retail pharmacies
  • MIRVASO is part of the Galderma CAREConnect Program†. Covered price is $20** and Not Covered/Cash is $75
  • MIRVASO still has excellent managed care coverage. This includes coverage on Ascent, Zinc and Emisar
  • Individual insurance requirements and out-of-pocket costs may vary

For a full explanation of details and benefits, please read the MIRVASO Letter from Galderma.

Size Item Number Indicated for Persons
0.33% 30 gm Pump MIR598035 18 years of age or older

Click to view full Prescribing Information for MIRVASO®.

Contact Wow! Customer Care or your FFF Sales Representative to place an order today.

MIRVASO® (brimonidine) topical gel, 0.33%* was studied in two 4-week pivotal trials and a 52-week, open-label study.2,3
In the pivotal trials, MIRVASO reduced the erythema of rosacea for up to 12 hours (22% vs 9%; P<.001) and began working in as little as 30 minutes on day 1 versus vehicle (28% vs 6%; P<.001).2,3
Primary endpoint: 2-grade improvement on both the Clinical Erythema Assessment and Patient Self-Assessment scales at hours 3, 6, 9, and 12 on day 29.1,2 At 12 hours on day 29, a 2-grade improvement of facial erythema was reported in 22% of study participants using MIRVASO compared to 9% of participants using vehicle gel (P<.001).2,3†
The Galderma® CAREConnect™ Program ("Program") is brought to you by Galderma Laboratories, L.P. ("Galderma"). The Program is only available at participating pharmacies for patients with commercial insurance or patients without insurance. Patients who are enrolled in a state or federal government run or government sponsored healthcare plan cannot participate in the Program. Any claim under the Program must be submitted by participating pharmacies to one of the Administrators of the Program. The Program is subject to applicable state and federal law and is void where prohibited by law, rule or regulation. In the event a lower cost generic drug that the FDA has designated as a therapeutic equivalent product is available for one of the Galderma products covered by the Program, or if the active ingredient of a Galderma product is available at a lower cost without a prescription, this offer will become void in California with respect to the Galderma product.
** "Covered" refers to commercial insurance product coverage without restrictions such as prior authorization approval, meeting step-edit and/or deductible requirements, and other criteria.
"Not Covered" refers to commercial insurance product coverage with restrictions or no product coverage. "Cash" is available to patients without insurance. Important Safety Information
Indication: MIRVASO® (brimonidine) topical gel, 0.33%* is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: MIRVASO Topical Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren's syndrome. Alpha-2 adrenergic agents can lower blood pressure. MIRVASO Topical Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of MIRVASO Topical Gel by children have been reported. Keep MIRVASO Topical Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.
* Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.

References: 1. MIRVASO Topical Gel [prescribing information]. Galderma Laboratories, L.P.: Nov 2017. 2. Fowler J Jr, Jackson JM, Moore A, et al; Brimonidine Phase III Study Group. Efficacy and safety of once-daily brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650-656. 3. Data on file. Galderma Laboratories, L.P.